On April 25, 2025 TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), reported its financial results for the fiscal year ending December 31, 2024, and provides a business update (Press release, TME Pharma, APR 25, 2025, View Source [SID1234652175]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Annual Report 2024, as approved by the management and supervisory boards on April 24, 2025, is available on TME Pharma’s website (www.tmepharma.com).

"TME Pharma achieved a number of significant clinical and regulatory milestones in 2024 and, as 2025 progresses, we remain committed to advancing the key initiatives that make up our strategic roadmap," said Aram Mangasarian, CEO of TME Pharma. "While strategic partnerships cannot be precisely timed, some of our discussions with potential partners and investors regarding strategic transactions for both NOX-A12 and NOX-E36 have been constructive. The regulatory validation of NOX‑A12’s Phase 2 randomized, controlled study design in glioblastoma by authorities in the US and Germany represented a key step in defining the clinical development pathway. Additionally, we have made important progress on getting NOX-E36 ready for clinical development in ophthalmic indications supported by promising preclinical data. While we pursue these clinical and strategic goals, we are also proactively preparing for contingencies to ensure operational continuity. Should strategic transactions not materialize by mid-2025, we will be ready to transition to a fully virtual and outsourced organizational structure, which would allow us to minimize costs while continuing to engage with industrial partners and investors to advance our clinical programs. By leveraging this flexible setup, we aim to preserve value for our shareholders."

Business and Clinical Highlights for 2024 and 2025 Year-to-Date

Brain Cancer (Glioblastoma) – Unprecedented Clinical Benefit

Glioblastoma is a highly aggressive and deadly form of brain cancer in which TME Pharma’s lead asset NOX-A12 has generated unprecedented clinical benefit in the GLORIA Phase 1/2 study. Newly diagnosed patients with glioblastoma tumors resistant to standard of care chemotherapy (MGMT unmethylated) and that are not amenable to complete surgical removal face a devastating prognosis of median overall survival (mOS) of approx. 10 months on standard of care. The development of effective treatments for these patients – TME Pharma’s target population in the GLORIA trial – is particularly challenging since these tumors tend to be more aggressive and less responsive to current therapies. Despite these unfavorable factors for the patients, TME Pharma’s development program of its lead asset, the CXCL12 inhibitor NOX-A12, suggests a strong signal of clinical benefit in this patient population.

In early March 2024, the Food and Drug Administration (FDA) cleared TME Pharma’s Investigational New Drug (IND) application on the basis of the protocol for its upcoming randomized Phase 2 trial in glioblastoma. Furthermore, in early April 2024, the company announced that the US FDA had granted Fast Track Designation for NOX-A12, in combination with radiotherapy and bevacizumab for newly diagnosed glioblastoma patients with chemotherapy-resistant disease and measurable tumor remaining after surgery.

Near-final efficacy data on glioblastoma patients treated with NOX-A12 combined with anti-VEGF and radiotherapy were presented by the lead investigator of the clinical trial, Dr. Frank Giordano, at a high-profile international cancer conference – the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress in September 2024 – revealing statistically significant improvement in survival for this triple combination over a standard of care reference cohort as well as NOX-A12 + radiotherapy alone (without anti-VEGF). The final median overall survival of the GLORIA 1/2 trial of the arm combining NOX-A12 with radiotherapy and bevacizumab achieved a remarkable 19.9 months. This exceeds what the company believes to be all relevant competitor studies conducted in the US or EU involving newly diagnosed, chemotherapy-resistant (MGMT unmethylated) glioblastoma patients.

Promising New Opportunities for NOX-E36 in Ophthalmology

TME Pharma’s second clinical stage asset, the CCL2 inhibitor NOX-E36, previously completed four clinical trials and has already been administered to 175 human subjects. While in an oncology setting NOX-E36 targets the tumor microenvironment by modifying the innate immune system, it has also demonstrated significant potential in addressing unmet medical need in ophthalmic diseases affected by scarring (fibrosis) and inflammation.

The anti-fibrotic mode of action of NOX-E36 has already been demonstrated in a relevant animal model, and the company believes that development in ophthalmological indications could be a promising opportunity to diversify its project portfolio. The company is pursuing resource-efficient possibilities to perform clinical studies such as investigator-initiated trials (IIT) funded and performed by research institutes, with TME Pharma supplying the drug. In parallel, TME Pharma is discussing with potential partners and venture capital firms the best way to develop NOX-E36 in the ophthalmology space with minimal or no financial contribution from TME Pharma’s shareholders.

TME Pharma has been collaborating with the Singapore Eye Research Institute (SERI) for several years and recent data from preclinical studies by SERI was selected for poster presentation at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in May 2025. The preclinical data show that mNOX-E36 offers a more favorable safety profile than standard of care mitomycin C (MMC), while demonstrating comparable efficacy in reducing post-operative inflammation and scarring (fibrosis) following glaucoma filtration surgery, a common procedure to reduce intraocular pressure. Unlike MMC, mNOX-E36 does not destroy blood vessels in the conjunctiva, potentially overcoming the substantial toxicity seen with MMC, which is a key limitation of this current standard treatment. Fibrosis and inflammation are also significant causes of treatment failure in back-of-the-eye indications, such as age-related macular degeneration and proliferative diabetic retinopathy. TME Pharma believes that anti-CCL2 therapy with NOX-E36 offers a novel therapeutic approach to address these issues and potential to access larger markets.

Due to these new findings and other unpublished data, TME Pharma and SERI have filed patent applications covering use of NOX-E36 in glaucoma filtration surgery and other ophthalmic diseases to support its development through a license to an industrial partner or the creation of a new corporate entity.

Post-Period Event – AI-Driven Drug Discovery

In January 2025, TME Pharma announced a partnership with aimed analytics, a cutting-edge data analytics company, to enhance TME Pharma’s capabilities to leverage artificial intelligence (AI) in drug discovery and optimization. The goal of the collaboration is to use AI to create new and improved drug candidates with accelerated timelines and without the need for resource-intensive laboratory testing. The collaboration should also strengthen TME Pharma’s corporate profile for strategic transactions and reinforce ongoing partnering discussions.

2024 Financial Summary

TME Pharma successfully strengthened its balance sheet by raising €7.6 million (gross) in 2024. Considering cash and cash equivalents of €3.2 million as of December 31, 2024, TME Pharma has financial visibility into June 2025.

As in prior years, TME Pharma has not generated any revenues. The Group – TME Pharma N.V., TME Pharma AG and TME Pharma Inc. – does not expect to generate any revenues from any product candidates that it develops until the Group either signs a licensing agreement or obtains regulatory approval and commercializes its products or enters into collaborative agreements with third parties and relies on dilutive and non-dilutive financing until it reaches profitability.

Research and development (R&D) expenses decreased 13% from K€ 2,652 in the fiscal year (FY) 2023 to K€ 2,296 in the FY 2024. The decrease in research and development expenses in 2024 compared to 2023 is primarily due to the clinical trial of NOX-A12 in brain cancer nearing completion, which required lower costs while at the same time generating more mature data. The pancreatic cancer clinical trial phase 2 protocol which has been approved by the FDA in the US has not been initiated, thereby keeping ongoing costs related to this clinical trial minimal. As a result, TME Pharma was able to decrease drug manufacturing costs, service fees and other costs related to the clinical trials and preclinical testing, in addition to lower personnel expenses, patent costs and consulting services, partly offset by higher other research and administrative expenses.

General and administrative (G&A) expenses decreased from K€ 2,989 in the FY 2023 to K€ 2,981 in the FY 2024. The decrease in G&A expenses in 2024 compared to 2023 is mainly driven by lower personnel expenses as well as lower public and investor relations expenses and other expenses, partly offset by higher legal, consulting and audit fees in connection with the financing transactions in 2024. Other general and administrative expenses comprise mainly of depreciation of rights of use assets and equipment, supervisory board remuneration, insurance premium, and ancillary leasing costs.

The finance income in the FY 2024 and 2023 was non-cash finance income. Finance income decreased from K€ 399 in the FY 2023 to K€ 32 in the FY 2024 as a result of ending the Atlas convertible bonds financing facility with Atlas Special Opportunities LLC (ASO). Finance income in 2024 mainly resulted from fair value adjustments of detachable warrants (ABSA Warrants) issued in connection with the preferential rights issue. In 2023, finance income of K€ 237 resulted from the derecognition of conversion rights in connection with the ASO financing upon conversion and redemption of the bonds and of K€ 162 fair value adjustments of ABSA Warrants issued in connection with the preferential rights issue.

Finance cost decreased from K€ 1,518 in the FY 2023 to K€ 503 in the FY 2024 as a result of ending the Atlas convertible bonds financing facility with ASO. Finance cost in the FY 2024 and 2023 was non-cash finance cost, except for transaction costs of K€ 16 in 2024 and K€ 4 in 2023 borne by the company in conjunction with the exercise of ABSA Warrants (in 2024) and the issuance of Atlas convertible bonds (in 2023) as well as K€ 2 in 2024 and K€ 13 in 2023 relating to interest expense for lease liabilities. Finance cost in the FY 2024 of K€ 489 relate to the initial recognition of ABSA Warrants amounting to K€ 113 as well as losses of K€ 376 from exercises of such warrants. Finance cost in the FY 2023 of K€ 1,505 relate to the ASO facility (contractually entered into in 2020 and ended in 2023, except for outstanding convertible bonds that were fully redeemed in cash in the FY 2024) and comprise losses on initial recognition of convertible bonds, conversion losses, conversion right derivatives, interest in exchange for the lock-up of convertible bonds issued and outstanding as well as transaction costs.

As a result of these factors, TME Pharma N.V. reports a net loss for FY 2024 of K€ 5,722 compared to K€ 6,736 in the FY 2023, a decrease of 15%.

Outlook for 2025

TME Pharma’s strategic focus for 2025 centers on maximizing the value of its clinical-stage assets, NOX‑A12 and NOX-E36, through strategic partnerships, licensing agreements, and potential M&A. The company is pursuing these opportunities while maintaining a lean cost structure and actively preparing for a contingency plan involving a fully outsourced organizational structure, should targeted financing or strategic transactions not materialize by June 2025.

NOX-A12 in Glioblastoma

Given the unprecedented clinical data and clear regulatory pathway, TME Pharma has strategically prioritized the development of NOX-A12 in first-line, chemotherapy resistant glioblastoma since the company believes this indication offers the fastest path to regulatory approval for NOX-A12 in the solid tumor space.

The partnering package for NOX-A12 in glioblastoma is particularly attractive due to:

Significant Clinical Benefit: Statistically significant improvement in survival for NOX-A12 with radiotherapy and anti-VEGF bevacizumab compared to both the standard of care reference cohort (p=0.003) and the cohort treated with NOX-A12 and radiotherapy alone (p=0.021).
Regulatory Validation: A clear regulatory pathway with a Phase 2 design approved by the US FDA and the German BfArM and enhanced regulatory interactions with Fast-Track status granted by the FDA in the US and Orphan Drug Designations granted in the US and EU.
Commercial Protection: Commercial protection provided by the Orphan Drug Designations and potentially also by the patent application filed in 2022 covering the NOX-A12, radiotherapy and bevacizumab combination, which would provide cover into the 2040s if granted.
Non-dilutive Funding: Non-dilutive financial support of more than €7 million pledged for the approved Phase 2 trial once it is initiated, including a €2.4 million grant from the German federal government.
Trial Readiness: Clinical trial grade (GMP) NOX-A12 sufficient to rapidly initiate the approved Phase 2 trial at the six centers already open in Germany.
NOX-E36 in Ophthalmology

TME Pharma recognizing NOX-E36 potential in ophthalmology has chosen to collaborate with the Singapore Eye Research Institute (SERI) to maximize efficiency and minimize required resources for further development of the asset.

The NOX-E36 program is poised for rapid advancement into the clinic on the basis of:

Strong Scientific Rationale: Compelling preclinical proof-of-concept and clinical data supporting CCL2 as a valid target.
Funding Opportunities: Funding for Phase 1b study potentially available through grants accessible to SERI
IP Protection: Joint patent applications filed for the use of NOX-E36 in eye diseases in March 2025.
Drug Availability: GMP drug supply manufactured and ready to use pending local ocular toxicity bridging for subconjunctival administration, ensuring a smooth transition to clinic.
Established Safety Profile: Excellent systemic safety and tolerability and dose-dependent pharmacologic activity established in 175 human subjects across previous clinical trials.
As part of its most recent business planning TME Pharma is pursuing several transaction structures in parallel for its drug candidates:

Out-licensing NOX-A12: Seeking an exclusive worldwide or regional out-licensing deal for NOX-A12 program to a pharmaceutical partner. The targeted transaction structure would bring in payments upon signature and significant regulatory and commercial milestones as well as providing for royalties on sales.
Out-licensing NOX-E36: Seeking an exclusive worldwide out-licensing deal for NOX-E36 program both by TME Pharma and collaboration partner SERI to a newly formed company funded by venture capital partners.
Asset Sale: Exploring the sale of the private operational subsidiary TME Pharma AG holding assets and intellectual property to a pharmaceutical partner or investor. This would result in TME Pharma N.V. holding either cash or shares of the acquiring entity.
Virtual Setup: As a contingency plan in case none of the above can be realized by June 2025, TME Pharma is preparing to change its organizational structure to allow it to continue pursuing the goals of financing, licensing or M&A transactions focused on its clinical stage assets, NOX‑A12 and NOX-E36 while minimizing costs by outsourcing essentially all functions to maintain and advance the programs and conduct industrial partner and investor outreach.
The outsourced staffing structure will likely be the most economically efficient option to manage collaborations and develop further transactions on NOX-A12 and NOX-E36 and so TME Pharma is actively preparing to transition to a fully outsourced staffing structure at the end of June 2025.

On April 25, 2025, United Therapeutics Corporation (the "Company") entered into a Credit Agreement (the "Credit Agreement") with the lenders referred to therein and Wells Fargo Bank, National Association ("Wells Fargo"), as administrative agent and as a swingline lender (Filing, 8-K, United Therapeutics, APR 25, 2025, View Source [SID1234652250]). The Credit Agreement provides for an unsecured, revolving credit facility of up to $2.5 billion (which facility may, subject to obtaining commitments from existing or new lenders for such increase and subject to other condition, be increased by up to $750 million in the aggregate). The facility matures five years after the closing date of the Credit Agreement, subject to an ability of the lenders thereunder, or certain of the lenders thereunder, to elect to extend the maturity date of their commitments by one year following a request for such extension by the Company in accordance with the terms of the Credit Agreement, up to a maximum of two such extensions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As of April 25, 2025, there are no subsidiaries of the Company required to be a guarantor and guarantee the Company’s obligations under the Credit Agreement. From time to time, one or more subsidiaries of the Company may be required to guarantee the Company’s obligations under the Credit Agreement.

At the Company’s option, the loan will bear interest at either an adjusted Term SOFR rate or a fluctuating base rate, in each case, plus an applicable margin that is determined on a quarterly basis based on the Company’s consolidated total leverage ratio (as calculated in accordance with the Credit Agreement).

The proceeds of borrowings under the Credit Agreement are available to refinance certain existing indebtedness of the Company and its subsidiaries and/or for working capital and other general corporate purposes. Upon closing of the Credit Agreement on April 25, 2025, the Company borrowed $200.0 million under the Credit Agreement, and used the funds to repay outstanding indebtedness under the 2022 Credit Agreement discussed under Item 1.02 below.

The Credit Agreement also contains customary affirmative and negative covenants that, among other things, limit the ability of the Company and its subsidiaries to (a) in the case of subsidiaries that are not guarantors of the credit facility, incur indebtedness; (b) grant liens; (c) solely with respect to credit parties under the credit facility, enter into a merger, consolidation or amalgamation; (d) liquidate, wind up or dissolve; or (e) sell all or substantially all of the property, business or assets of the Company and its subsidiaries taken as a whole. In addition, as of the last day of each fiscal quarter, the Company must not permit a consolidated ratio of total indebtedness to EBITDA to be greater than 3.50 to 1.00 (which ratio may, upon consummation of (i) certain qualifying acquisitions, be increased to 4.00 to 1.00 for four fiscal quarters following such acquisition and (ii) certain qualifying inbound licensing transactions, be increased to 4.00 to 1.00 for the first two fiscal quarters following such inbound licensing transaction and 3.75 to 1.00 for the next two fiscal quarters following such inbound licensing transaction) and its consolidated interest coverage ratio to be less than 3.00 to 1.00, in each case calculated in accordance with the Credit Agreement.

The Credit Agreement contains customary events of default, including a change of control. Upon the occurrence and continuation of an event of default, all amounts due under the Credit Agreement and the other loan documents become (in the case of a bankruptcy event), or may become (in the case of all other events of default and at the option of the lenders), immediately due and payable.

The foregoing summary is qualified in its entirety by reference to the copy of the Credit Agreement attached hereto as Exhibit 10.1.

On April 25, 2025 FORE Biotherapeutics, a registration stage biotherapeutics company dedicated to developing targeted therapies to treat patients with cancer, reported new plixorafenib results from the Phase 1/2a clinical trial that demonstrate that circulating tumor DNA (ctDNA) accurately detects BRAF mutations in tumor biopsies and change in variant allele frequency (VAF) of BRAF mutation in ctDNA may be a surrogate marker for monitoring disease (Press release, Fore Biotherapeutics, APR 25, 2025, View Source [SID1234652143]). The data is being presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2025, taking place April 25-30 in Chicago.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Plixorafenib was designed to inhibit mutated oncogenic BRAF V600, without causing paradoxical MAPK pathway activation, and also confers dimer–breaking properties and activity against non-V600 BRAF alterations," said Rona Yaeger, M.D., Gastrointestinal Medical Oncologist and Early Drug Development Specialist at Memorial Sloan Kettering Cancer Center. "The data from this clinical study, demonstrating molecular response and durable clinical responses (including when given without a MEK inhibitor) and the absence of emergent MAPK pathway alterations on treatment, further support the unique mechanism of action and the potential to benefit patients with BRAF-altered malignancies."

"These results are important because they show additional evidence of the strong clinical activity of plixorafenib, in both BRAF V600 mutations and BRAF fusions," said Stacie Peacock Shepherd, M.D., Ph.D., Chief Medical Officer of Fore. "In addition, this analysis also demonstrated high concordance of ctDNA BRAF mutations with biopsy tissue and changes in ctDNA corresponded closely to tumor size across tumor types; thus, liquid biopsies with widely used next-generation sequencing methodologies may provide a straightforward approach to identify appropriate patients for plixorafenib treatment, monitor disease status, and response. We are excited to share this data, along with the study design for our ongoing registrational FORTE study in BRAF altered advanced solid tumors, as we develop plixorafenib to help patients with BRAF driven tumors and generate further data to inform treatment."

The ctDNA results are from over 70 plixorafenib-treated patients and were an exploratory endpoint from a previously completed Phase 1/2a study. Utilizing next-generation sequencing (NGS), the plasma ctDNA results demonstrated high concordance with tissue biopsy at baseline across tumor types and mutations. Declines of V600 VAF% were observed in 85% of study participants after one cycle of plixorafenib treatment. Declines of class 2 and class 3 BRAF alterations in ctDNA were also observed. In participants with available paired tumor biopsies, decreases in pERK validated ctDNA results and demonstrated the suppression of the MAPK pathway at clinically relevant exposures. In addition, participants with V600E-mutated advanced solid tumors, early changes in V600E VAF% may predict response to plixorafenib, as responders had larger decreases in VAF% from baseline to cycle 2. In longitudinal samples, changes in ctDNA corresponded to tumor size across tumor types, suggesting that ctDNA may be a surrogate marker for monitoring disease. Compared to acquired mutations driving resistance to early generation BRAF inhibitors, no new mutations in MAPK pathway genes were found following plixorafenib treatment, supporting the dimer–breaker property and novel mechanism of action of plixorafenib from the early generation BRAF inhibitors. In participants without response, co-occurrent drivers at baseline included RAS, MAPK-associated or NF1 mutation, including melanoma patients who all received prior MAPKi therapies.

Also being presented at AACR (Free AACR Whitepaper) 2025 is a trial in progress poster showcasing the global FORTE master protocol with a basket design, including three monotherapy sub-protocols in patients with BRAF fusions, rare BRAF V600-mutated tumors, and BRAF V600 primary recurrent central nervous system tumors. An interim analysis is planned for each of the monotherapy baskets during 2025. A fourth, exploratory sub-protocol will assess preliminary activity of plixorafenib in BRAF V600-mutated select solid tumors. Alongside primary and key secondary endpoints of overall response rate, duration of response, safety, progression-free survival, overall survival, and pharmacokinetics, key exploratory endpoint of each of the four sub-protocols is a longitudinal ctDNA assessment.

Poster Presentation Details:

Title: Circulating tumor DNA analysis of patients with BRAF-mutated advanced unresectable solid tumors treated with plixorafenib (FORE8394/PLX8394) in Phase 1/2a study
Poster Session: Liquid Biopsy Circulating Nucleic Acids 1
Date and Time: Monday, April 28, 2025, 2:00 – 5:00 p.m. CT
Abstract Number: 3248
Presenter: Jessica C. Jang, Fore Biotherapeutics

Title: FORTE: A phase 2 master protocol assessing plixorafenib for BRAF-altered cancers
Poster Session: Late Breaking and Clinical Trials – Phase II and Phase III Clinical Trials in Progress
Date and Time: Tuesday, April 29, 2025, 2:00 – 5:00 p.m. CT
Abstract Number: CT247
Presenter: Macarena I. de la Fuente, M.D., Sylvester Comprehensive Cancer Center

On April 25, 2025 Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules targeting RNA and RNA regulation for oncology and neurological disorders, reported that preclinical data from its lead program, RGT-61159 were presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) 2025 Annual Meeting, which is being held from April 25-30, 2025, in Chicago, IL (Press release, Rgenta Therapeutics, APR 25, 2025, View Source [SID1234652159]). The data demonstrate robust anti-tumor activity of RGT-61159 in several cell-derived xenograft (CDX) models of AML and synergistic benefit when combined with standard of care for AML highlighting the potential of RGT-61159 to treat a broad AML patient population.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The data presented at the AACR (Free AACR Whitepaper) meeting highlight the ability of RGT-61159 to reduce levels of both MYB RNA transcripts and correspondingly MYB protein in a dose dependent fashion, which translates to potent killing activity in cells that overexpress MYB," said Travis Wager, Ph.D. co-founder and chief scientific officer. "Importantly, we see robust antitumor activity with RGT-61159 across a range of AML models that carry genetic alterations that are common in patients with AML highlighting its potential to treat a broad AML patient population."

"Using RGT-61159, which specifically acts at the RNA level, we are able to address MYB which has been shown to function as an oncogenic driver in a variety of cancers including AML, colorectal cancer (CRC) and adenoid cystic carcinoma (ACC), and until now, has been a difficult target to drug," said Simon Xi, Ph.D., cofounder and chief executive officer of Rgenta. "Our ongoing Phase 1a/b clinical trial of RGT- 61159 in patients with relapsed or refractory ACC or CRC is advancing well and we look forward to broadening that program and initiating a new Phase 1/2 study of RGT-61159 in adults with AML/high risk myelodysplastic syndromes the second half of 2025."

In a poster titled RGT-61159, Best-in-class Oral Small Molecule Inhibitor of MYB via Selective RNA Splicing Alteration, Synergistic Anti-Tumor Activity When Combined with Standards of Care in Leukemia Disease Models Harboring AML Common Genetic Lesions, data were presented highlighting the close correlation between the elimination of MYB RNA and protein by RGT-61159 and its potent killing activity against leukemia and lymphoma cancer cell lines that over express MYB, demonstrating on-target therapeutic activity of this potent, orally available small molecule. RGT-61159 also inhibited AML cell proliferation and downregulated the expression of master oncogenes controlled by MYB, including MYC, BCL2, FLT3 and IDH1. Data from several CDX models of AML with genetic alterations seen commonly in AML, demonstrated the robust anti-tumor activity of tolerated doses of RGT-61159 and synergistic activity both in vitro and in vivo when administered in combination with agents used in AML standard of care.

About RGT-61159
RGT-61159 is an orally available small molecule designed to specifically modulate splicing of the transcription factor MYB resulting in the inhibition of the oncogenic MYB protein and potential cell death of the cancer cells that overexpress the MYB protein. MYB acts as a master regulator of cell proliferation, self-renewal, and differentiation processes and its aberrant expression has been demonstrated in multiple forms of human cancer including adenoid cystic carcinoma (ACC), acute myeloid leukemia (AML), T-cell acute lymphoblastic leukemia (T-ALL), colorectal cancer (CRC), small cell lung cancer (SCLC) and breast cancer. Rgenta is evaluating RGT-61159 in an ongoing multi-center, open-label Phase 1a/b clinical trial in patients with advanced relapsed or refractory ACC or CRC. The Phase 1a/b study is designed to evaluate safety, tolerability, pharmacokinetics, target engagement and clinical efficacy of RGT-61159 in patients with ACC or CRC. Additional information about the Phase 1a/b clinical trial can be accessed at ClinicalTrials.gov (NCT06462183).

On April 25, 2025 Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, reported that 18 abstracts, including one oral presentation, have been accepted for presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2025, on April 25 – 30 in Chicago (Press release, Tempus, APR 25, 2025, View Source [SID1234652176]). Tempus researchers will showcase scientific and clinical research that highlight the transformative impact of AI on oncology treatment and patient outcomes.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Tempus is proud to showcase a comprehensive collection of scientific research this year, highlighting the impact of our multimodal dataset and AI-enabled diagnostic solutions on cancer research," said Kate Sasser, PhD, Chief Scientific Officer at Tempus. "AACR stands as a leading forum for cancer research, and we look forward to presenting our findings alongside our collaborators in Tempus’ home city of Chicago."

Research highlights include:

Oral Presentation: Investigating the clinical landscape and biological impact of SF3B1 hotspot mutations in breast cancer
Date/Time: April 27, 2025; 4:40 PM – 4:45 PM CT
Location: To be announced

Overview: This study examines the implications of SF3B1 hotspot mutations in breast cancer, focusing on genetic profile, survival outcomes, and biological impacts, by analyzing de-identified data from Tempus’ multimodal real-world database consisting of 420 breast cancer patients with SF3B1 mutations. Innovative genome editing in isogenic breast cell lines revealed that SF3B1 mutations negatively impact cell growth and tumor development. The findings support the utility of SF3B1 mutations as potential therapeutic targets and underscore the importance of understanding their role in cancer biology, with ongoing research aimed at uncovering the mechanisms behind hotspot-specific effects.
Poster Presentation: Genetic and clinical landscape of NUTM1 structural variants
Date/Time: April 28, 2025; 2:00 PM – 5:00 PM CT
Location: Section 34
Overview: Within Tempus’ multimodal real-world database, researchers identified 59 patients with a primary diagnosis of NUT carcinoma—an aggressive cancer—81% of whom had a confirmed NUTM1 fusion. Notably, there were 106 additional patients who had a NUTM1 fusion without a corresponding initial NUT carcinoma diagnosis, suggesting a potentially significant underdiagnosis rate. The study found a variety of fusion gene partners, with certain cancer types showing enrichment of specific fusions. With a median overall survival of just over 5 months, the findings suggest that certain cancer types with a high enrichment of NUTM1 fusions may benefit from universal next-generation sequencing to ensure accurate diagnosis and potentially improve outcomes for patients with high-risk cancer types.
Poster Presentation: A longitudinal, circulating tumor molecular response biomarker as a predictor of clinical outcomes in a real-world cohort of patients with advanced solid tumors treated with tyrosine kinase inhibitors
Date/Time: April 29, 2025; 9:00 AM – 12:00 PM CT

Location: Section 45

Overview: In a study analyzing advanced cancer patients, researchers evaluated the prognostic value of changes in circulating tumor DNA tumor fraction (ctDNA TF) during tyrosine kinase inhibitor (TKi) therapy. The study, which consisted of 109 patients from Tempus’ multimodal real-world database, found that molecular responders had significantly longer real-world overall survival (rwOS) than molecular non-responders across various cancer types. The findings suggest that ctDNA TF may serve as a biomarker to predict molecular response to TKi therapy, potentially guiding treatment decisions and improving patient outcomes in a real-world setting.
Collaborator-led Poster Presentation: Enhancing TCR-T with a Fas-based switch receptor boosts T cell engraftment, persistence, and anti-tumor activity in models of hard-to-treat PRAME solid tumor indications
Date/Time: April 29, 2025; 9:00 AM – 12:00 PM CT

Location: Section 39

Overview: T-knife Therapeutics is developing a FAS-based switch receptor (FAS-TNFR) to target PRAME-positive solid tumors, designed to enhance T cell activity and overcome the hostile tumor microenvironment. Utilizing Tempus multi-modal data, T-Knife analyzed a large database of tumor samples to identify the inhibitory ligands most frequently found in PRAME-expressing indications and to understand in depth the pattern of expression of PRAME and inhibitory ligands in different patient populations. These insights provided by Tempus were crucial for T-knife to select the optimal switch receptor from their armoring toolbox and determine appropriate target populations for their upcoming clinical trials (Figures 1A, 2D, and 3A-C present Tempus-driven data and insights).